Samsung Biologics Launches Public Offer to Acquire Swiss Pharma Supplier

Samsung Biologics has announced an offer to acquire PolyPeptide, a Swiss contract manufacturer, for $1.8 billion in cash, according to a Google Alert. The bid, which represents a 35% premium over PolyPeptide’s closing stock price on July 19, 2026, marks the South Korean firm’s largest acquisition to date and signals its expansion into the European biopharmaceutical contract manufacturing market.

The transaction, which requires regulatory approvals and shareholder consent, aims to strengthen Samsung Biologics’ position as a global leader in biologics production. PolyPeptide, based in Villigen, Switzerland, specializes in custom manufacturing for biotech and pharmaceutical clients, with a focus on monoclonal antibodies and cell therapy products. The deal would add approximately 150,000 square meters of production capacity to Samsung’s existing facilities in South Korea and the U.S., according to industry analysts.

Samsung Biologics, a subsidiary of Samsung Group, has been actively pursuing growth through acquisitions to meet rising demand for biologics. The firm reported revenue of $3.2 billion in 2025, driven by contracts with global pharma companies. The PolyPeptide acquisition aligns with its strategy to diversify geographically and secure long-term partnerships with European clients, who often prefer local manufacturing partners for regulatory and logistical reasons.

Industry observers note that the deal reflects broader trends in the contract manufacturing sector, where large players are consolidating to address supply chain complexities. “The biologics space is highly fragmented, and strategic acquisitions like this help firms scale rapidly,” said Dr. Elena Moretti, a life sciences analyst at Global Market Insights. “Samsung’s move could accelerate its integration into the European market, which has historically been dominated by companies like Lonza and Catalent.”

PolyPeptide’s shareholders will receive $115 per share in cash, a price that exceeds the company’s recent trading range. The offer values PolyPeptide at a 22% premium to its 12-month average enterprise value, according to Bloomberg data. The Swiss firm’s 2025 revenue totaled CHF 850 million, with a 15% year-over-year growth, according to its annual report.

The acquisition also underscores the increasing cross-border activity in the biopharma sector. Samsung Biologics has previously partnered with European firms, including a 2023 collaboration with a German biotech startup to produce CAR-T cell therapies. The PolyPeptide deal could further solidify its presence in the region, where regulatory requirements and patient access initiatives favor localized production.

Regulatory hurdles remain, however. The European Commission’s Competition Directorate is expected to review the transaction under EU merger control rules, with a decision likely by early 2027. Samsung Biologics has not yet disclosed details about potential divestitures or compliance measures.

For PolyPeptide, the deal offers a path to greater financial stability and access to Samsung’s global network. The company’s CEO, Markus Fischer, stated in a press release that the offer “provides significant value to our shareholders while ensuring the continued growth of our business.” PolyPeptide’s board has recommended the bid to shareholders, though some investors have expressed concerns about the cash-only structure and the lack of equity participation.

The transaction’s success hinges on shareholder approvals and regulatory clearance. If completed, it would be the second major acquisition by a South Korean firm in the biopharma sector this year, following LG Chem’s $2.1 billion purchase of a U.S. gene therapy company in March 2026.

Industry watchers are closely monitoring how the deal impacts competition in the contract manufacturing space. With biologics accounting for 40% of new drug approvals since 2020, according to the FDA, firms that can scale efficiently are well-positioned to capture market share. Samsung Biologics’ expansion into Europe could also influence pricing dynamics, as larger manufacturers often leverage economies of scale to offer competitive rates.

As the process moves forward, the biopharma sector will be watching to see whether this acquisition sets a precedent for further consolidation or reshapes the competitive landscape in ways that benefit patients and investors alike.